Aisling Capital Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
9

- Investments
-
231
- Portfolio
-
19
- Exits
-
147

Aisling Capital General Information
Description
Founded in 2000, Aisling Capital is a venture capital firm based in New York, New York. The firm prefers to invest in seed-stage, early-stage, and growth-stage companies. The firm seeks to invest in the healthcare, and life sciences sectors in Mid Atlantic, South, and West Coasts.
Contact Information
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
PE/Buyout
Primary Office
- 888 Seventh Avenue
- 12th Floor
- New York, NY 10106
- United States
+1 (212) 000-0000
Aisling Capital Investments & Acquisitions (231)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Treeline Biosciences | 11-Oct-2022 | Early Stage VC | 00000 | Drug Discovery | Startup | |
00000 000000000 | 12-Sep-2022 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 000000 000000 00 |
0000 000 | 14-Jun-2022 | 00000 00000 | 000.00 | Drug Discovery | Pre-Clinical Trials | 000000 000000 00 |
000000 00000000000 | 03-Nov-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | |
000000 00000000000 | 07-Sep-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 0000 000000 00 |
0000000 000000000 | 15-Jul-2021 | 00 000000000 | Media and Information Services (B2B) | Profitable | ||
00000 | 09-Jul-2021 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 1 | 000000 0000000 |
0000000 | 01-Jul-2021 | 0000000000 | Other Healthcare Services | Profitable | 000000 0000 | |
Antios Therapeutics | 09-Apr-2021 | Early Stage VC | 0000 | Drug Discovery | Clinical Trials - Phase 2 | |
Treeline Biosciences | 09-Apr-2021 | Early Stage VC | 00000 | Drug Discovery | Startup |
Aisling Capital Exits (147)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Medical Knowledge Group | 01-Feb-2022 | Buyout/LBO | 00.000 |
000000000 00000000 | 25-Jun-2021 | 000 | 00000 |
00000 0000 0000000 | 24-Jun-2021 | 000 | 00000 |
0000000 0000000000 | 07-May-2021 | 000 | 00000 |
0000 000000000 | 16-Apr-2021 | 000000000 00000000 | |
000000 000000 | 16-Apr-2021 | 000 | 00000 |
00000 | 09-Apr-2021 | 000 | 000.00 |
00000000 000 | 10-Feb-2021 | 0000000 000000 | 00000 |
Aimmune Therapeutics | 13-Oct-2020 | Merger/Acquisition | 00.00 |
Spruce Biosciences | 09-Oct-2020 | IPO | 0000 |
Aisling Capital Fund Performance
Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
---|
Aisling Capital Investments by Industry, Year, and Region
Aisling Capital Team (35)
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Robert Wenzel | Chief Financial Officer & Chief Compliance Officer, Legal | New York, NY | |||
Andrew Schiff MD | Managing Partner | 00 | 0 | 0 | New York, NY |
Steven Elms | Managing Partner | 00 | 0 | 0 | New York, NY |
Eric Aguiar MD | Partner | 00 | 0 | 0 | New York, NY |
Sunny Reddy | Principal | New York, NY |
Aisling Capital Co-Investors (110)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Cormorant Asset Management | 6 | 0 |
![]() |
![]() |
|
Boxer Capital | 0 | 0 |
![]() |
![]() |
|
Fidelity Management & Research | 0 | 0 |
![]() |
![]() |
|
Abingworth | 0 | 0 |
![]() |
![]() |
|
Citadel Enterprise Americas | 0 |
![]() |
![]() |